Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Breast cancer regimen 'raises carpal tunnel risk'

  • Comment

A breast cancer drug treatment increases the chances of a woman developing carpal tunnel syndrome, according to research.

Women with the disease who took tamoxifen for two-three years and then took exemestane were less likely to develop further cancer and were at less risk of death.

However, those taking exemestane developed more musculoskeletal problems, such as fractures or joint pains, than women remaining on the five-year course of tamoxifen: a respective 42.4% and 33.2%.

Women with hormone-sensitive breast cancer are typically given a five-year regimen after surgery.

The findings came out of tests involving 4,700 women in 37 countries, known as the Intergroup Exemestane Study.

Researchers said 2.8% of the exemestane group suffered carpal tunnel syndrome but only 0.3% of the other group suffered the same.

The findings are published in the journal Lancet Oncology, giving more information about the musculoskeletal side-effects of the drug.

The study was conducted by Leiden University Medical Centre in The Netherlands, Imperial College London and the Institute of Cancer Research.

Commenting on the study, the institute’s Judith Bliss said: “We found more than half of patients who developed this side-effect had surgery. But the vast majority were able to continue their treatment for breast cancer and did not experience carpal tunnel syndrome once their treatment had concluded.”

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.